

2nd August, 2017

BSE Limited P J Towers, Dalal Street, Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	--

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and Regulation 30 of Listing Regulations read with Schedule III of Listing Regulations, we wish to enclose herewith:

- a) Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2017, as approved by the Board of Directors at its meeting held today; and
- b) Limited Review Report issued by Haribhakti & Co. LLP., Statutory Auditors of the Company for the quarter ended 30th June, 2017.

We also wish to enclose herewith copy of the Press Release proposed to be issued in respect of the said Financial Results; and extract of Unaudited Consolidated Financial Results for the quarter ended 30th June, 2017 being published in the Newspapers.

The Board Meeting commenced at 10.30 a.m. and concluded at 11.55 a.m.

Kindly take the same on your record.

Thanking you,

For **Wockhardt Limited**



Narendra Singh
Company Secretary

Encl.: As above



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs. In Lakhs except per share data)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

	PARTICULARS	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
		30/06/2017	31/03/2017	30/06/2016	31/03/2017
	(Refer notes below)	Unaudited	Audited (Refer note 3)	Unaudited	Audited
1	(a) Revenue from operations	43,990	54,054	61,335	229,752
	(b) Other income	2,250	1,760	1,736	24,831
	Total income	46,240	55,814	63,071	254,583
2	Expenses				
	(a) Cost of materials consumed	11,721	10,770	15,792	53,522
	(b) Purchase of stock-in-trade	7,167	8,053	10,342	42,866
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,809	3,424	(1,809)	(1,432)
	(d) Employee benefits expense	13,094	12,797	13,365	52,322
	(e) Finance costs	4,292	4,074	4,412	16,872
	(f) Depreciation and amortisation expense	2,654	2,531	2,573	10,566
	(g) Exchange fluctuation (gain) / loss	304	(816)	(109)	(1,140)
	(h) Other expenses	16,645	14,820	18,337	69,129
	Total expenses	58,686	55,653	62,903	242,705
3	Profit / (Loss) before tax (1-2)	(12,446)	161	168	11,878
4	Tax expense:				
	Current tax	-	-	(182)	(2,530)
	Deferred tax credit/(charge)	2,288	(752)	1,647	4,364
5	Net Profit / (Loss) after tax (3-4)	(10,158)	(591)	1,633	13,712
6	Other Comprehensive Income				
	a) Items that will not be reclassified to Profit or Loss (consisting of re-measurement of net defined benefit liability/asset)	(60)	(174)	(22)	(240)
	b) Income tax relating to items that will not be reclassified to Profit or Loss	20	57	7	79
	c) Other Comprehensive Income (net of tax) (6a ± 6b)	(40)	(117)	(15)	(161)
7	Total Comprehensive Income (5 ± 6c)	(10,198)	(708)	1,618	13,551
8	Paid-up equity share capital (face value of Rs. 5/- each)	5,528	5,527	5,525	5,527
9	Other Equity excluding Revaluation Reserves as per balance sheet				116,405
10	Earnings per share (face value of Rs. 5/- each) (*not annualised)				
	(a) Basic (Rs.)	(9.19)*	(0.54)*	1.48*	12.40
	(b) Diluted (Rs.)	(9.99)*	(0.54)*	1.47*	12.26




Notes To Standalone Results :-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 02, 2017. The results for the current quarter and quarter ended June 30, 2016 have been subjected to limited review by the Statutory Auditors of the Company.
- 2) During the quarter, the Company has allotted 15,200 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.
- 3) Figures for the quarter ended March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the financial year 2016-17.
- 4) The Company is exclusively into Pharmaceutical business Segment.
- 5) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

Aurangabad
Date : August 02, 2017

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045808



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikailhana, Aurangabad - 431 006
 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
 CIN: L24230MH1999PLC120720
 Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. in Lakhs except per share data)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2017				
PARTICULARS	3 MONTHS ENDED 30/06/2017	3 MONTHS ENDED 31/03/2017	3 MONTHS ENDED 30/06/2016	YEAR ENDED 31/03/2017
	Unaudited	Audited (Refer Note 5)	Unaudited	Audited
(Refer Notes Below)				
1) a) Revenue from Operations	89,106	86,353	109,083	401,461
b) Other Income	3,702	5,629	1,690	11,425
Total Income	92,808	91,982	110,773	412,886
2 Expenses				
(a) Cost of materials consumed	22,055	18,148	26,573	89,190
(b) Purchase of Stock-in-trade	15,014	19,608	17,053	79,604
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4,244	6,020	(1,937)	(2,587)
(d) Employee benefits expense	23,844	22,147	25,125	96,651
(e) Finance Cost	6,111	5,890	4,858	22,527
(f) Exchange fluctuation (gain) / loss	(1,927)	(1,239)	990	1,342
(g) Depreciation and amortisation expense	3,718	3,708	3,638	14,893
(h) Other expenses	31,883	38,095	33,745	135,981
Total Expenses	104,942	112,377	110,045	437,601
3 Profit / (Loss) before exceptional items and tax (1-2)	(12,134)	(20,395)	728	(24,715)
4 Exceptional Items loss / (gain) (Refer Note 4)	35,819	-	-	-
5 Profit / (Loss) before tax (3 ± 4)	(47,953)	(20,395)	728	(24,715)
6 Tax Expenses				
Current tax	(193)	2,666	(539)	(1,037)
Deferred tax (charge) / credit	1,889	(2,993)	1,481	3,148
7 Profit / (Loss) after tax (5-6)	(46,257)	(20,722)	1,670	(22,604)
8 Share of Profit/(Loss) of Associate	-	-	-	-
9 Non - Controlling Interest	(5,291)	(3,250)	81	(3,032)
10 Net Profit/(Loss) after taxes, non-controlling interest & share of profit / (loss) of associates (7 ± 8 ± 9)	(40,966)	(17,472)	1,589	(19,572)
11 Other comprehensive income				
a) Items that will not be reclassified to Profit or Loss (consisting of re-measurement of net defined benefit liability / asset)	441	(976)	(786)	(3,365)
b) Income tax relating to items that will not be reclassified to Profit or Loss	(30)	126	82	380
c) Items that will be reclassified to Profit or Loss (Consisting of Exchange differences on translating the financial statements of foreign operations)	3,673	(7,152)	63	(15,172)
d) Other comprehensive income (net of tax) (11a ± 11b ± 11c)	4,084	(8,002)	(641)	(18,157)
12 Total Comprehensive Income (7 ± 8 ± 11 (d))	(42,173)	(28,724)	1,029	(40,761)
Attributable to Equity shareholders of the Company	(37,466)	(24,396)	1,037	(35,222)
Attributable to Non Controlling Interest	(4,707)	(4,328)	(8)	(5,539)
13 Paid-up equity share capital (face value Rs. 5/- each)	5,528	5,527	5,525	5,527
14 Other Equity excluding Revaluation Reserves as per balance sheet				328,144
15 Earnings Per Share: (face value of Rs. 5 each) (*Not Annualised)				
(a) Basic (Rs.)	(37.06)*	(15.81)*	1.44*	(17.71)
(b) Diluted (Rs.)	(37.72)*	(15.81)*	1.43*	(17.71)



Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 02, 2017. The results for the current quarter and quarter ended June 30, 2016 have been subjected to limited review by the Statutory Auditors of the Company.
- 2) These Consolidated Results relate to Wockhardt Limited (the Holding Company) and its Subsidiaries (together constitute the Group) and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) During the quarter, the Company has allotted 15,200 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.
- 4) **Exceptional Item:** During the quarter ended June 30, 2017, the on-going commercial litigation between the Company and two of its subsidiaries namely Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP) in relation to a supply contract with Cephalon Inc. (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva) before the High Court in London, United Kingdom, was settled at cost of GBP 43 mn to the Group. The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement, the ongoing litigation stands closed.
- 5) Figures for the quarter ended March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the financial year 2016-17.
- 6) Key Financials on Standalone basis

(Rs In Lakhs)


Particulars	QUARTER ENDED 30/09/2017	QUARTER ENDED 31/03/2017	QUARTER ENDED 31/03/2016	YEAR ENDED 31/03/2017
	Unaudited	Audited	Unaudited	Audited
Revenue from operations	43,990	54,054	81,335	229,752
Profit / (Loss) Before Tax	(12,445)	161	169	11,878
Profit / (Loss) After Tax	(10,158)	(501)	1,633	13,712

Note: The Unaudited stand alone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 7) The Group is exclusively into Pharmaceutical business Segment.
- 8) For List of Subsidiaries as on June 30, 2017 please refer Annexure.
- 9) Previous periods / year figures have been recast / regrouped to conform to the current period's presentation.

Aurangabad
Date : August 02, 2017

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 8 of Consolidated unaudited Results for the Quarter ended June 30, 2017

List of Subsidiaries as on June 30, 2017

- 1 Wockhardt Infrastructure Development Limited
- 2 Wockhardt UK Holdings Limited
- 3 Wockhardt Bio AG [Formerly, Wockhardt EU Operations (Swiss) AG]
- 4 Wockhardt Europe Limited
- 5 CP Pharmaceuticals Limited
- 6 Wallis Group Limited
- 7 The Wallis Laboratory Limited
- 8 Wallis Licensing Limited
- 9 Wockhardt Farmaceutica Do Brasil Ltda
- 10 Z & Z Services GmbH (formerly, Esparma GmbH)
- 11 Wockhardt UK Limited
- 12 CP Pharma (Schweiz) AG
- 13 Wockpharma Ireland Limited
- 14 Pinewood Healthcare Limited
- 15 Pinewood Laboratories Limited
- 16 Wockhardt France (Holdings) S.A.S.
- 17 Niverpharma S.A.S.
- 18 Laboratoires Pharma 2000 S.A.S.
- 19 Laboratoires Negma S.A.S.
- 20 Negma Beneulex S.A.
- 21 Phytex S.A.S.
- 22 Wockhardt Holding Corp
- 23 Morton Grove Pharmaceuticals Inc.
- 24 MGP Inc
- 25 Wockhardt USA LLC
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Nigeria Limited
- 29 Wockhardt Bio [R]
- 30 Wockhardt Bio Pty Ltd
- 31 Wockhardt Bio Ltd



Limited Review Report on the Unaudited Standalone Financial Results for the quarter ended June 30, 2017 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors

Wockhardt Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Wockhardt Limited** ('the Company') for the quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



HARIBHAKTI & CO. LLP


Chartered Accountants

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognised accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No. 103523W/W100048



Bhavik L. Shah

Partner

Membership No. 122071



Place: Mumbai

Date: August 2, 2017

Limited Review Report on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2017 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors of
Wockhardt Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Wockhardt Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter ended June 30, 2017 ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Holding Company's management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We believe that the review procedures performed by us is sufficient and appropriate to provide a basis for our reporting on the Statement.




HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted as above, and based on the consideration of interim financial information furnished to us by the management referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognised accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the financial results of Eleven (11) subsidiaries included in the Statement, whose financial results reflects total revenue of ₹ 1,042 Lakhs and total profit after tax of ₹ 84 Lakhs for the quarter ended June 30, 2017, as considered in the Statement. These financial results are not reviewed by their auditors and have been furnished to us by the Management and our reporting on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such un-reviewed financial results. According to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our review report on the Statement is not modified in respect of our reliance on the financial information certified by the Management.

For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048



Bhavik L. Shah
Partner
Membership No: 122071



Place: Mumbai
Date: August 02, 2017

Aurangabad, 2nd August, 2017

Wockhardt Q1FY18 Net Sales at Rs.891 crore

	Q1-FY18	Q4-FY17	Q1-FY17
	Apr - Jun	Jan - Mar	Apr - Jun
	2017	2017	2016
	INR Cr	INR Cr	INR Cr
Sales	891	864	1,091
EBITDA before R&D	(7)	(87)	193
EBITDA % to Sales	-0.8%	-10.1%	17.7%
EBITDA	(79)	(177)	85
EBITDA Margins %	-8.9%	-20.5%	7.8%
PBT before exceptional item	(121)	(204)	7
Exceptional item ^[1]	(358)	-	-
PBT after exceptional item	(479)	(204)	7
Profit After Tax	(410)	(175)	16
PAT Margins %	-46.0%	-20.3%	1.5%
EPS	(37.1)	(15.8)	1.4

^[1] Refer note on Settlement of commercial litigation.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter for Financial Year 2018, today.

Settlement of commercial litigation:

During the quarter ended June 30, 2017, the on-going commercial litigation between the Company and two of its subsidiaries namely Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP) in relation to a supply contract with Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva) before the High Court in London, United Kingdom, was settled at cost of GBP 43 mn to Wockhardt Group.

The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed.

PRESS RELEASE

WOCKHARDT

**LIFE
WINS**

Wockhardt Limited

| D-4, MIDC, Chikalthana |
| Aurangabad |
| Maharashtra | | 431 006 |
| India |
| Tel.: +91-22-2653 4444 |
| www.wockhardt.com

Business review for the quarter:

Despite uncertainties hovering over GST implementation in India, ongoing US FDA related matters and genericisation of some of the products of the Company in USA, the overall sales during the quarter improved over the trailing quarter of Q4FY17 (quarter on quarter) by about Rs. 27 crore, mainly on account of enhanced business in UK.

While on-going expenses on remedial measures (for US FDA related issues) impacted the profitability, the Company's focus on cost containments and rationalisation gave positive impact thereby significantly reducing losses quarter on quarter. The continued strategic focus of the Company in R&D initiatives though impacted the profitability of the Company during the quarter, it would be noteworthy to mention that such strategic R&D spends are for the future even if they are expensed off.

UK Business in GBP terms grew by 29% over Q4FY17. The Company received 1 new approval in UK market in Q1FY18.

India Business of the Company de grew by 8% in Q1FY18 over Q4FY17. 4 New Products were launched in Q1FY18.

Emerging Market Business of the Company grew by 11% in Q1FY18 compared to Q1FY17.

The company's continued pursuit in creating strong Intellectual Property (IP) base resulted into filing of 20 patents during the Quarter ended 30th June, 2017 taking the cumulative filings to 2,924. The company was granted 9 patents during the quarter and now totally holds 562 patents.

The company continued to focus in Research & Development with quarterly spent at Rs.72 crore (8% to sales) and including capital expenditure is at 10% to sales for the quarter ended 30th June, 2017.

Capital expenditure of Rs.51 crore was incurred in Q1FY18.

The company made 1 new filing in Q1FY18 and received 1 new approval taking the cumulative ANDA's pending for approval at 80. 1 tentative ANDA approval received in US.

Quarter ended 30th June, 2017

Consolidated revenue for Q1FY18 was Rs.891 crore and EBITDA was at Rs.(79) crore.

International Business contributed 66% of the Total Revenues in Q1FY18.

EBITDA before R&D spend was Rs.(7) crore in Q1FY18 compared to Rs.193 crore in the Q1FY17.

Ireland Business grew by 25% in Euro terms in Q1FY18 and by 9% in INR terms Q1FY18

Proposed Issue of Securities :

Pursuant to the approval by the Board of Directors of the Company in the meeting held on 4th May, 2017 for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (“QIP”) to eligible investors through an issuance of equity shares or other eligible securities for an amount not exceeding Rs 1,000 crores, notice of postal ballot was sent to the shareholders of the Company during the quarter. The resolution was passed with 99.95% voted in favour of the resolution on 8th June, 2017 and shall be valid for one year.

About Wockhardt :

Wockhardt is a Global Pharmaceutical and Biotech company employing over 10,000 people and 27 nationalities with presence in USA, UK, Ireland, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 66% of its global revenues coming from international businesses. Wockhardt is home to 600 plus scientists, of whom 70 plus are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive. Wockhardt’s entire Anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
 Global Headquarters: Wockhardt Towers, Bandra Kuria Complex, Bandra (East), Mumbai 400 051
 CIN:L24230MH1999PLC120720
 Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

**Extract of Unaudited Consolidated Financial Results
 For the Quarter ended June 30, 2017**

Rs in Lakhs (except per share data)

Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
	30/06/2017	31/03/2017	30/06/2016	31/03/2017
	Unaudited	Audited	Unaudited	Audited
Total Income from Operations	89,106	86,353	109,083	401,461
Net Profit / (Loss) (before tax, Exceptional and / or Extraordinary items)	(12,134)	(20,395)	728	(24,715)
Net Profit / (Loss) before tax (after Exceptional and / or Extraordinary items) (Refer Note 4)	(47,953)	(20,395)	728	(24,715)
Net Profit / (Loss) after tax (after Exceptional and / or Extraordinary items)	(40,966)	(17,472)	1,589	(19,572)
Total Comprehensive Income / (Loss) (Comprising of Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	(42,173)	(28,724)	1,029	(40,761)
Paid-up Equity Share Capital (Rs. 5/- each)	5,528	5,527	5,525	5,527
Other Equity excluding Revaluation Reserves as shown in the Audited balance sheet of the previous year				328,144
Earnings per share (Face value Rs 5 each) * Not annualised				
Basic	(37.06)*	(15.81)*	1.44*	(17.71)
Diluted	(37.72)*	(15.81)*	1.43*	(17.71)

Notes:

1. Information on Standalone Financial Results are as follows:

Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
	30/06/2017	31/03/2017	30/06/2016	31/03/2017
	Unaudited	Audited	Unaudited	Audited
Total Income from Operations	43,990	54,054	61,335	229,752
Profit / (Loss) Before Tax	(12,446)	161	168	11,878
Profit / (Loss) After Tax	(10,158)	(591)	1,633	13,712

2. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 02, 2017. The results for the current quarter and quarter ended June 30, 2016 have been subjected to limited review by the Statutory Auditors of the Company.

3. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website (www.wockhardt.com).

4. Exceptional Item: During the quarter ended June 30, 2017, the on-going commercial litigation between the Company and two of its subsidiaries namely Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP) in relation to a supply contract with Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva) before the High Court in London, United Kingdom, was settled at cost of GBP 43 mn to the Group.

The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed.

For WOCKHARDT LIMITED



H F KHORAKIWALA
 CHAIRMAN
 DIN : 00045608

Aurangabad
 Date : August 02, 2017